LB PHARMACEUTICALS INC (LBRX) — research page

US · us-cm-kg/NASDAQ/LBRX · as of 2026-11-08

Identity and listing

The issuer is LB PHARMACEUTICALS INC, listed on NASDAQ under ticker LBRX, with ISIN US50180M1080. The LEI is not on the record. The security type is Corporate, the segment is not on the record, the sector is 2834 Pharmaceutical Preparations, and the jurisdiction is United States, Delaware. The issuer is listed and not halted.

The disclosure read

The record holds 71 filings in the twelve months to 2026-11-08, across 36 filing days. The median gap between filing days is 7 days. The latest filing is dated 2026-11-05, 3 days before the record date, and is of type results. The exchange median for NASDAQ is 6.0 days of cadence gap, 52 filings and 5.0 days of latency across 4359 issuers. The sector median for 2834 Pharmaceutical Preparations is 6.0 days of cadence gap, 63.0 filings and 4.0 days of latency across 526 issuers. By type, the window holds 3 agm_egm, 5 corporate_news, 5 director_change, 17 directors_dealings, 11 prospectus, 22 regulatory_filing and 8 results filings.

window 2025-11-08 to 2026-11-08 · the node's disclosure lines, as get_filings serves them

Auditor

The auditor of record is not on the record, because the latest annual report cover carries no dei:AuditorName tag. The auditor location is not on the record. The market's record holds no auditor changes for the issuer.

Events and halts

The record holds no listing, delisting or name change lines for the issuer. The domicile change is not on the record, as EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, as the exchanges' tier transfers are not EDGAR filings. The halt flag is clear: listed, not halted.

Orderability

The outcome is not determinable under rule version acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, because the chapter's orderability section carries no client categories, so the outcome cannot name its client category. The chapter is as of 2026-11-04.

rule acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1 · chapter as of 2026-11-04 · the full outcome: get_orderability

Coverage

The issuer's investor-relations page names 12 research houses: BMO Capital Markets, Canaccord Genuity, Clear Street, Craig-Hallum, Guggenheim, H.C. Wainwright, Leerink, Needham, Piper Sandler, Roth Capital Partners, Stifel and Wolfe Research.

Open research

No openly published research notes were found for the issuer, so the record holds none.

Licensed

Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.

As-of depth

The issuer's years sealed are 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12.

Sources

8 source pages are named on this page; every value above carries its own source page and read date in the numbers.

10.1

https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)

10.2

https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data (identity.isin)

10.3

https://data.sec.gov/submissions/CIK0001691082.json (identity.jurisdiction)

10.4

https://mcp.us-cm-kg.ai/events/NASDAQ/LBRX (the disclosure lines)

10.5

https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)

10.6

https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)

10.7

https://ir.lbpharma.com/investors/stock-information/ (coverage)

10.8

https://mcp.us-cm-kg.ai/record/NASDAQ/LBRX (the record)

Read it by agent

The same page, signed and receipted: get_research at https://mcp.getissuer.ai/mcp with {"isin":"US50180M1080"}. Twins: .md · .json. Written: Claude through the platform account, Haiku class; one pass; checked against the numbers. Page hash sha256:b1a3ceff6f7ea573.